Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Core Insights - The ALPHA3 study is a significant milestone for Allogene, with the first data expected in early Q2 [2] Group 1 - Cema-cel is a key focus of the ALPHA3 study, which aims to provide insights into its efficacy and safety [2] - The design of the ALPHA3 study is structured to evaluate the performance of cema-cel in a clinical setting [2]